[Correspondence] Extending survival for people with hepatitis C using tobacco dependence treatment

The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.

Source: LANCET - November 3, 2017 Category: General Medicine Authors: Coral Gartner, Alleshia Miller, Billie Bonevski Tags: Correspondence Source Type: research